A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

Recruiting now Phase 2 NCT07276581

Run by AstraZeneca · for 18 and older · All sexes

What this study is about

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.

Who can join (things the study team will check)

* Inclusion * Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening. * Moderately-to-severely active RA as defined by: a. \>= 6 swollen joints on 66SJC and \>= 6 tender joints on 68TJC; b. CRP \> upper limit of normal. * Have a positive ACPA at screening. * A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi. * A history of at least 12 weeks treatment and \>= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation. * Exclusion * History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible. * Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.…

Where this trial is running

Research Site, Glendale, Arizona, United States
Research Site, Prescott Valley, Arizona, United States
Research Site, Tucson, Arizona, United States
Research Site, La Jolla, California, United States
Research Site, San Dimas, California, United States
Research Site, San Leandro, California, United States
Research Site, Aurora, Colorado, United States
Research Site, Boynton Beach, Florida, United States
Research Site, Jacksonville, Florida, United States
Research Site, South Miami, Florida, United States
Research Site, Tampa, Florida, United States
Research Site, Winter Haven, Florida, United States

+ 132 more sites.

Who to contact

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07276581.

Open the interactive checklist for this trial →

Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.

Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.